Common use of Milestone Event Milestone Payment Clause in Contracts

Milestone Event Milestone Payment. First [**] filing with the [**] for a Class of [**] Engineered T-Cell Product that differs from the Class of [**] Engineered T-Cell Product that was the subject of [**]

Milestone Event Milestone Payment. First [**] filing with the [**] for a Class of [**] Engineered T-Cell Product that differs from the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event A.4 above on the basis of clause (b) of Section 1.21 but is the same Class as the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event A.4 above on the basis of Gene Target [**]

Milestone Event Milestone Payment. First [**] filing with the [**] for a Class of [**] Engineered T-Cell Product that differs from the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event D.3 above on the basis of clause (b) of Section 1.15 but is the same Class as the Class of [**] [**]

Milestone Event Milestone Payment. First [**] filing with the [**] Acceptance for a Class of [**] Engineered T-Cell Product that differs from the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event A.2 above on the basis of clause (a) of Section 1.15 and from the Class of [**]Engineered T-Cell Product that was the subject of a prior achievement of this Milestone Event on the basis of clause (a) of Section 1.15 [**]

Milestone Event Milestone Payment. First [**] filing with the [**] Acceptance for a Class of [**] Engineered T-Cell Product that differs from the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event A.2 above on the basis of clause (a) of Section 1.21 and from the Class of [**] Engineered T-Cell Product that was the subject of a prior achievement of this Milestone Event on the basis of clause (a) of Section 1.21 [**]

Milestone Event Milestone Payment. First [**] filing with subject of Milestone Event A.4 and Milestone Event B.1 above on the [**] for a basis of clause (b) of Section 1.15 but is the same Class of [**] Engineered T-Cell Product that differs from as the Class of [**] Engineered T-Cell Product that was the subject of [**]Milestone Event A.4 above on the basis of Gene Target and is not subject to Milestone Event B.2 above

Milestone Event Milestone Payment. First [**] filing with Milestone Event A.4 above on the [**] for a basis of clause (b) of Section 1.15 but is the same Class of [**] Engineered T-Cell Product that differs from as the Class of [**] Engineered T-Cell Product that was the subject of [**]Milestone Event A.4 above on the basis of Gene Target

Milestone Event Milestone Payment. First [**] filing with the [**] for a Class of [**] Engineered T-Cell Product that differs from the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event A.4 and Milestone Event B.1 above on the basis of clause (b) of Section 1.15 but is the same Class as the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event A.4 above on the basis of Gene Target [**]

Milestone Event Milestone Payment. First [**] filing with the [**] for a subsequent Class of [**] Engineered T-Cell Product that differs from the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event D.3 and Milestone Event D.7 above on the basis of clause (b) of Section 1.15 but is the same Class as the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event D.3 above on the basis of Gene Target [**]

Milestone Event Milestone Payment. First [**] filing with the [**] for a Class of each [**] Engineered T-Cell Product that differs from the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event A.4 above on the basis of clause (a) of Section 1.21 and from the Class of [**] Engineered T-Cell Product that was the subject of a prior achievement of this Milestone Event on the basis of clause (a) of Section 1.21 [**]

Milestone Event Milestone Payment. First [**] filing with the [**] for a subsequent Class of [**] Engineered T-Cell Product that differs from the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event D.3 and Milestone Event D.7 above on the basis of clause (b) of Section 1.21 but is the same Class as the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event D.3 above on the basis of Gene Target [**]

Milestone Event Milestone Payment. First [**] filing with the [**] for a Class of [**] Engineered T-Cell Product that differs from the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event A.5 above on the basis of clause (b) of Section 1.21 but is the same Class as the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event A.5 above on the basis of Gene Target [**]

Milestone Event Milestone Payment. First [**] filing with from the [**] for a for a Class of [**] Engineered T-Cell Product that differs from the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event A.4 and Milestone Event B.1 above on the basis of clause (b) of Section 1.21 but is the same Class as the Class of [**]] Engineered T-Cell Product that was the subject of Milestone Event A.4 above on the basis of Gene Target and is not subject to Milestone Event B.4 above [**] TOTAL $50,000,000

Milestone Event Milestone Payment. First [**] filing with but is the [**] for a same Class of [**] Engineered T-Cell Product that differs from as the Class of [**] Engineered T-Cell Product that was the subject of [**]Milestone Event D.3 above on the basis of Gene Target

Milestone Event Milestone Payment. First [**] filing with the [**] for a Class of [**] Engineered T-Cell Product that differs from the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event A.4 and Milestone Event B.1 above on the basis of clause (b) of Section 1.21 but is the same Class as the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event A.4 above on the basis of Gene Target [**]

Milestone Event Milestone Payment. First [**] filing with the [**] for a Class of [**] Engineered T-Cell Product that differs from the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event D.3 above on the basis of clause (b) of Section 1.15 but is the same Class as the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event D.3 above on the basis of Gene Target [**]

Milestone Event Milestone Payment. First [**] filing with the [**] Acceptance for a Class of [**] Engineered T-Cell Product that differs from the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event A.2 above on the basis of clause (a) of Section 1.15 and from the Class of [**] Engineered T-Cell Product that was the subject of a prior achievement of this Milestone Event on the basis of clause (a) of Section 1.15 [**]

Milestone Event Milestone Payment. First [**] filing with the [**] for a Class of [**] Engineered T-Cell Product that differs from the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event A.4 above on the basis of clause (b) of Section 1.15 but is the same Class as the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event A.4 above on the basis of Gene Target [**]

Milestone Event Milestone Payment. First [**] filing with the [**] for a subsequent Class of [**] Engineered T-Cell Product that differs from the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event D.3 and Milestone Event D.7 above on the basis of clause (b) of Section 1.21 but is the same Class as the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event D.3 above on the basis of Gene Target [**]

Milestone Event Milestone Payment. First [**] filing with the [**] Acceptance for a Class of [**] Engineered T-Cell Product that differs from the Class of [**]Engineered T-Cell Product that was the subject of Milestone Event A.2 above on the basis of clause (a) of Section 1.21 and from the Class of [**] Engineered T-Cell Product that was the subject of a prior achievement of this Milestone Event on the basis of clause (a) of Section 1.21 [**]

Milestone Event Milestone Payment. First [**] filing with the [**] for a Class of [**] ]Engineered T-Cell Product that differs from the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event A.4 and Milestone Event B.1 above on the basis of clause (b) of Section 1.15 but is the same Class as the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event A.4 above on the basis of Gene Target [**]

Milestone Event Milestone Payment. First [**] filing with from the [**] for a Class of for each [**] Engineered T-Cell Product that differs from the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event A.4 above on the basis of clause (a) of Section 1.15 and from the Class of [**] Engineered T-Cell Product that was the subject of a prior achievement of this Milestone Event on the basis of clause (a) of Section 1.15 [**]

Milestone Event Milestone Payment. First [**] filing with the [**] for a Class of [**] Engineered T-Cell Product that differs from the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event A.5 and Milestone Event B.1 above on the basis of clause (b) of Section 1.21 but is the same Class as the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event A.5 above on the basis of Gene Target [**]

Milestone Event Milestone Payment. First [**] filing with the [**] for a Class of [**] Engineered T-Cell Product that differs from the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event D.3 above on the basis of clause (b) of Section 1.21 but is the same Class as the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event D.3 above on the basis of Gene Target [**]